IQV Stock Chart & Stats
$3290.00
$0.00(0.00%)
At close: 4:00 PM EDT
$3290.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2,800.00 - $4,658.00
Previous CloseN/A
Volume0.00
Average Volume (3M)57.00
Market Cap
$720.81B
Enterprise Value$46.62K
Total Cash (Recent Filing)$2.08B
Total Debt (Recent Filing)$16.24B
Price to Earnings (P/E)31.6
Beta0.01
Next Earnings
Nov 04, 2026EPS Estimate
56.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding164,600,000
10 Day Avg. Volume67
30 Day Avg. Volume57
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4,619.35Price Target Upside40.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)220.49
Revenue Forecast (FY)$296.01B
Bulls Say, Bears Say
Bulls Say
Bookings And BacklogRobust bookings and backlog provide IQVIA with meaningful forward revenue visibility and indicate sustained client demand for R&D services. A 1.22 book-to-bill and growing near-term backlog support service activity and revenue conversion over the coming quarters.
AI-Enabled DifferentiationAI capabilities are becoming embedded in IQVIA’s clinical-development offering, potentially improving delivery speed while differentiating its services. Reported gains in study startup, recruitment and data cleaning can strengthen client value and support broader adoption.
Cash GenerationStrong operating and free cash flow provide internal funding for debt service, technology investment and shareholder returns. TTM free cash flow of $2.94B and conversion near 94% of net income indicate durable cash generation, despite some annual variability.
Bears Say
Elevated LeverageNet leverage of 3.59x and gross debt of $15.999B reduce financial flexibility and increase sensitivity to earnings weakness. Refinancing may extend maturities, but leverage remains a constraint on capital allocation and the capacity to absorb adverse conditions.
Margin PressureGross-margin compression and flat full-year EBITDA margin guidance suggest that productivity gains are being absorbed by pass-throughs, FX and lower-margin acquisitions. If this mix persists, revenue growth may translate less efficiently into profit and cash generation.
Backlog Quality ReviewThe review of inactive trials introduces uncertainty around the quality and durability of reported backlog, even though management said it should not affect historical results or next-12-month reported revenue. This may complicate forecasting and backlog interpretation.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings Inc’s price range in the past 12 months?
IQVIA Holdings Inc lowest stock price was $2800.00 and its highest was $4658.00 in the past 12 months.
What is IQVIA Holdings Inc’s market cap?
IQVIA Holdings Inc’s market cap is $720.81B.
When is IQVIA Holdings Inc’s upcoming earnings report date?
IQVIA Holdings Inc’s upcoming earnings report date is Nov 04, 2026 which is in 55 days.
How were IQVIA Holdings Inc’s earnings last quarter?
IQVIA Holdings Inc released its earnings results on Jul 28, 2026. The company reported $54.656 earnings per share for the quarter, beating the consensus estimate of $52.609 by $2.047.
Is IQVIA Holdings Inc overvalued?
According to Wall Street analysts IQVIA Holdings Inc’s price is currently Undervalued.
Does IQVIA Holdings Inc pay dividends?
IQVIA Holdings Inc does not currently pay dividends.
What is IQVIA Holdings Inc’s EPS estimate?
IQVIA Holdings Inc’s EPS estimate is 56.67.
How many shares outstanding does IQVIA Holdings Inc have?
IQVIA Holdings Inc has 164,600,000 shares outstanding.
What happened to IQVIA Holdings Inc’s price movement after its last earnings report?
IQVIA Holdings Inc reported an EPS of $54.656 in its last earnings report, beating expectations of $52.609. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of IQVIA Holdings Inc?
Currently, no hedge funds are holding shares in MX:IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4,619.35 (40.41% Upside)
$4,619.35 (40.41% Upside)
Blogger Sentiment
Bullish
MX:IQV Sentiment 64%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $505.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
IQVIA Holdings Inc
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
IQV Company Deck
IQV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall: the company beat Q2 guidance across revenue, adjusted EBITDA and adjusted EPS, reported accelerating organic growth and robust bookings momentum (notably a 19.3% YoY increase in quarterly R&DS bookings and a 1.22 book-to-bill). Management raised full-year revenue, EBITDA and EPS guidance and highlighted meaningful AI-driven wins and operational productivity gains. Headwinds include a reduced FX tailwind, pass-through revenue pressure, added leverage and some lower-margin acquisition contribution; management expects these non-operational items to offset some margin gains for the year. On balance, the highlights (revenue and earnings beats, strong bookings/backlog, FCF growth, AI traction and raised guidance) significantly outweigh the lowlights.View all MX:IQV earnings summariesIQV Revenue Breakdown
40.63% Technology & Analytics Solutions
54.54% Research & Development Solutions
4.83% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$4,619.35
▲(40.41% Upside)